Under the research collaboration with professor Jack Schalken (laboratory of experimental urology), InteRNA’s lentiviral-based microRNA (miRNA) overexpression library will be applied in multi-parametric, high-throughput functional screening assays to identify the biological role of individual miRNAs and novel therapeutic targets in prostate cancer.
Roel Schaapveld, COO of InteRNA Technologies, said: “We are very excited about this collaboration with professor Schalken, a renowned investigator in the prostate cancer field, as it allows for functional screens in diverse cell based assays embedded in a lab with extensive knowledge of prostate cancer.”
Mr Schalken of Radboud University Nijmegen Medical Centre (UNMC) said: “Through the collaboration with InteRNA we gain access to a unique functional tool to identify microRNAs that are implicated in prostate carcinogenesis.”